Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Mallinckrodt
Moodys
Medtronic
Queensland Health
Boehringer Ingelheim
Federal Trade Commission
Cantor Fitzgerald
UBS
McKinsey

Generated: August 18, 2017

DrugPatentWatch Database Preview

IZBA Drug Profile

« Back to Dashboard

What is the patent landscape for Izba, and when can generic versions of Izba launch?

Izba is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty countries.

The generic ingredient in IZBA is travoprost. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the travoprost profile page.

Summary for Tradename: IZBA

Patents:4
Applicants:1
NDAs:1
Bulk Api Vendors: see list37
Patent Applications: see list1,334
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:IZBA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
IZBA
travoprost
SOLUTION/DROPS;OPHTHALMIC204822-001May 15, 2014DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
IZBA
travoprost
SOLUTION/DROPS;OPHTHALMIC204822-001May 15, 2014DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
IZBA
travoprost
SOLUTION/DROPS;OPHTHALMIC204822-001May 15, 2014DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
IZBA
travoprost
SOLUTION/DROPS;OPHTHALMIC204822-001May 15, 2014DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
IZBA
travoprost
SOLUTION/DROPS;OPHTHALMIC204822-001May 15, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: IZBA

Drugname Dosage Strength RLD Submissiondate
travoprostOphthalmic Solution0.003%Izba12/30/2015

International Patent Family for Tradename: IZBA

Country Document Number Estimated Expiration
Portugal2265251► Subscribe
Australia2009225824► Subscribe
European Patent Office2265251► Subscribe
South Korea101586357► Subscribe
Canada2716994► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IZBA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014029Lithuania► SubscribePRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
00540Netherlands► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
2012017Lithuania► SubscribePRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1920764/01Switzerland► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002
C0045France► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Novartis
Argus Health
US Department of Justice
Covington
Federal Trade Commission
Chinese Patent Office
Teva
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot